Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Parekh, Jay, Parikh, Kaushal, Reuss, Joshua E., Friedlaender, Alex, Addeo, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326100/
https://www.ncbi.nlm.nih.gov/pubmed/37249833
http://dx.doi.org/10.1007/s11912-023-01430-4
Descripción
Sumario:PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with recent approvals in the peri-operative space, is now poised to transform the systemic treatment paradigm for localized and locally-advanced NSCLC. SUMMARY: In this review, we focus on neoadjuvant ICB in resectable NSCLC, highlighting the pre-clinical rationale for neoadjuvant ICB, early clinical trials, randomized phase 3 trial data, and future directions for resectable NSCLC. GRAPHICAL ABSTRACT: [Image: see text]

Ejemplares similares